← Back to headlines
Fund Makes $170 Million Bet on Biotech Stock Amid FDA Review
A specific fund has invested $170 million in a biotech stock that has seen a 1,040% increase in value over the past year, coinciding with an FDA review for its breast cancer drug.
13 Mar, 14:48 — 13 Mar, 14:48
Sources
Showing 1 of 1 sources
Related Stories
Oil Prices Rise After Previous Day's Sharp Drop
just now
Expert Questions Significance of France's Credit Rating Amid Lower Borrowing Costs for Italy and Spain
41m ago
Homeowners Over 50 Can Save Thousands Annually with Overlooked Tax Breaks
1h ago
Greek Government's Surplus Policies Criticized for Impact on Citizens' Livelihoods
1h ago